Table 1

Characteristics of subjects with positive and negative BAL cultures for Aspergillus at age 5 years, presented as number of subjects in each category (%) or median (IQR) values

CharacteristicsPositive Aspergillus
n=28 (17.9%)
Negative Aspergillus
n=128 (82.1%)
P value
Female17 (60.7)60 (46.9)0.23
Meconium ileus7 (25.0)25 (19.5)0.34
Children in BAL arm of ACFBAL study15 (53.6)64 (50.0)0.52
Children in OP arm of ACFBAL study13 (46.4)64 (50.0)
Received gentamicin8 (28.6)35 (27.3)0.53
Received anti-staphylococcal prophylaxis until their first birthday6 (21.4)27 (21.1)0.56
Children with positive Pseudomonas aeruginosa in BAL culture at age
5 years
4 (14.3)13 (10.2)0.36
Children with positive P. aeruginosa in BAL culture prior to age 5 years8 (28.6)37 (28.9)0.59
Body mass index z-score at BAL0.16
(−0.31, 0.58)
0.01
(−0.41, 0.43)
0.45
Cumulative dosage of intravenous tobramycin (not associated with eradication therapy) (mg)33
(0.00, 49.5)
64
(0.0, 670.0)
0.03
Cumulative dosage of intravenous tobramycin received (mg)*2667.5
(247.5, 4203.8)
0.0
(0.0, 2344.5)
0.001
Cumulative dosage of inhaled tobramycin received (mg)56 282.5
(8449.5, 72 750)
0.0
(0.0, 36 600)
0.06
Cumulative dosage of intravenous and oral antibiotics (not associated with eradication therapy) (mg)†11 784.9
(1458.7, 43 099.5)
7323.5
(468.75,
33 186.5)
0.26
Minimum annual temperature at geographic region at baseline (°C)10.6
(−4.53, 11.8)
11.9
(4.4, 12.8)
0.14
Maximum annual temperature at geographic region at baseline (°C)27.2
(20.6, 31.4)
24.1
(20.6, 26.7)
0.045
Number of P. aeruginosa eradication therapy courses received before BAL2 (1, 2)0.5 (0, 1)0.001
Number of ‘all-cause’ CF-related hospitalisations before age 5 years BAL3.5 (1, 7)3 (1.2, 5.5)0.03
Number of all pulmonary exacerbations before age 5 years BAL12 (6.5, 17.5)13 (10, 17)0.66
Number of pulmonary exacerbations requiring hospitalisation before age 5 years BAL3 (1, 4)2 (1, 4)0.90
  • *Combined with an anti-pseudomonal beta-lactam antibiotic.

  • †Antibiotics other than tobramycin and not associated with eradication therapy (eg, intravenous cefuroxime, oral macrolides, amoxicillin-clavulanate and cotrimoxazole).

  • ACFBAL, Australasian Cystic Fibrosis Bronchoalveolar Lavage study;BAL, bronchoalveolar lavage;CF, cystic fibrosis;OP, oropharyngeal; n, number of children contributing data.